
Sign up to save your podcasts
Or
New GLP-1 weight-loss drugs have already hit $50 billion in annual sales – and look to have plenty of room to grow.
Portfolio Manager Dan Lyons joins this episode of Global Perspectives to provide an update on popular GLP-1 weight-loss therapies and discuss whether sales of the drugs can continue to grow and the impact on the overall healthcare sector.
4.7
1414 ratings
New GLP-1 weight-loss drugs have already hit $50 billion in annual sales – and look to have plenty of room to grow.
Portfolio Manager Dan Lyons joins this episode of Global Perspectives to provide an update on popular GLP-1 weight-loss therapies and discuss whether sales of the drugs can continue to grow and the impact on the overall healthcare sector.
1,358 Listeners
478 Listeners
191 Listeners
2,162 Listeners
1,683 Listeners
269 Listeners
715 Listeners
258 Listeners
859 Listeners
1,264 Listeners
8,385 Listeners
244 Listeners
179 Listeners
43 Listeners
3 Listeners
76 Listeners